The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome. Bortezomib-resistant myeloma cells down-regulate the activation status of the unfolded protein response, and up-regulate β2 proteasome activity. T...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Haematologica
Hoofdauteurs: Kraus, Marianne, Bader, Juergen, Geurink, Paul P., Weyburne, Emily S., Mirabella, Anne C., Silzle, Tobias, Shabaneh, Tamer B., van der Linden, Wouter A., de Bruin, Gerjan, Haile, Sarah R., van Rooden, Eva, Appenzeller, Christina, Li, Nan, Kisselev, Alexei F., Overkleeft, Herman, Driessen, Christoph
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Ferrata Storti Foundation 2015
Onderwerpen:
Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4591768/
https://ncbi.nlm.nih.gov/pubmed/26069288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.109421
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items